Anu Laboratories Limited, a Hyderabad-based manufacturer of bulk drug intermediates, has decided to raise an amount worth Rs 250 crore, by way of issuing debt, equity or any other security.

The pharmaceutical firm is present in manufacturing of bulk drug intermediates for the last 13 years and having leadership in most of its products being manufactured namely i. e 2,4-Dichloro-5 Fluoro Acetophenone and other high quality intermediates such as Chlorohexanone, 1 ,3-Dibromo Propane, Methy1-4 (4-Chloro 1 oxo butyl), Di-Methyl Acetate etc.,

According to reports, the raised funds would be used for further expansion, acquisition of facilities, enhancement of business horizon and exploring the opportunities in organic and inorganic growth.

Presently, Anu Laboratories is setting up a US FDA-compliant API manufacturing facility at Visakhapatnam, with an investment worth Rs 63 crore. The facility is expected to go on stream by October 2009.

Apart from latest announcement, the boards of directors of the company have recommended the bonus shares in the ratio of 1: 1 i. e. one bonus share for every one share held by the share holders.

Anu Labs has reported a net profit of Rs 11.46 crore on net sales of Rs 114.28 crore till the third quarter ended December 31, 2008, as against Rs 18.08 crore and Rs
150.408 crore respectively in FY08.

At 12:40 pm, the scrip of the company was trading at Rs 37, marginally down compared to previous close.